Lankeit M, Konstantinides M. - Mortality risk assessment and the role of thrombolysis in pulmonary embolism. Clin Chest Med, 2010, 31, 759-769.
Lin HJ, Wolf PA, Kelly-Hayes M, et al. - Stroke severity in atrial fibrillation. The Framingham Study. Stroke, 1996, 27, 1760-1764. (Pubitemid 26332500)
Schulman S, Beyth RJ, Kearon C, et al. - Hemorrhagic complications of anticoagulant and thrombolytic treatment: american college of chest physicians evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133, 257-298.
Go AS, Hylek EM, Chang Y, et al. - Anticoagulation therapy for stroke prevention in atrial fibrillation : how well do randomized trials translate into clinical practice? JAMA, 2003, 290, 2685-2692. (Pubitemid 37475596)
Crowther MA, Berry LR, Monagle PT, et al. - Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol, 2002, 116, 178-186. (Pubitemid 34122079)
Stangier J, Clemens A. - Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost, 2009, 15, S1-S9
Eriksson BI, Dahl OE, Rosencher N, et al. - Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement : the RE-MODEL randomized trial. J Thromb Haemost, 2007, 5, 2178-2185. (Pubitemid 47617868)
Eriksson BI, Dahl OE, Rosencher N, et al. - Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement : a randomised, double-blind, non-inferiority trial. Lancet, 2007, 370, 949-956. (Pubitemid 47393577)
Connolly SJ, Ezekowitz MD, Yusuf S, et al. - Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Medicine, 2009, 361, 1139-1151.
Schulman S, Kearon C, Kakkar AK, et al. - Dabigatran versus warfarine in the treatment of acute venous thromboembolism. N Engl J Med, 2009, 361, 2342-2352.
Schulman S, Kakkar AK, Schellong SM, et al.- A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Am Soc Hematology, 2011, Annual Meeting; San Diego, CA. Abstract 205.
Oldgren J, Budaj A, Granger CB, et al. - Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy : a randomized, double-blind, phase II trial. Eur Heart J, 2011, 32, 2781-2789.
Kubitza D, Becka M, Voith B, et al. - Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY-59 7939, an oral, direct, factor Xa inhibitor. Clin Pharmacol Ther, 2005, 78, 412-421. (Pubitemid 41393676)
Eriksson BI, Kakkar AK, Turpie AG, et al. - Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br, 2009, 91, 636-644.
Bauersachs R, Berkowitz SD, Brenner B, et al. - Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010, 363, 2499-2510.
Romualdi E, Donadini MP, Ageno W. - Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study). Expert Rev Cardiovasc Ther, 2011, 9, 841-844.
Patel MR, Mahaffey KW, Garg J, et al. - Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365, 883-891.
Cohen A. - LBCT IV Session 3015. Presented at: ACC 60th Annual Scientific Sessions; April 2-5, 2011; New Orleans, LA.
Mega JL, Braunwald E, Wiviott SD, et al. - Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2011, 366, 9-19.
He K, Luettgen JM, Zhang D, et al. - Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet, 2011, 36, 129-139.
Lassen MR, Raskob GE, Gallus A, et al. - Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2) : a randomised double-blind trial. Lancet, 2010, 375, 807-815.
Lassen MR, Gallus A, Raskob GE, et al. - Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med, 2010, 363, 2487-2498.
Granger CB, Alexander JH, McMurray JJ, et al. - Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365, 981-992.
Alexander JH, Lopes RD, James S, et al. - Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med, 2011, 365, 699-708.
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. - Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med, 2011, 365, 2167-2177.
Ogata K, Mendell-Harary J, Tachibana M, et al. - Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol, 2010, 50, 743-753.
Raskob G, Cohen AT, Eriksson BI, et al. - Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost, 2010, 104, 642-649.
Eriksson BI, Quinlan DJ, Weitz JI. - Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet, 2009, 48, 1-22.
Samama MM, Guinet C. - Laboratory assessment of new anticoagulants. Clin Chem Lab Med, 2011, 49, 761-772.
van Ryn J, Stangier J, Haertter S, et al. - Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost, 2010, 103, 1116-1127.
Kazmi RS, Lwaleed BA. - New anticoagulants : how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol, 2011, 72, 593-603.
